ESAD

CompletedPhase NAResults posted

Progression Delaying Effect of Escitalopram in Alzheimer's Disease

Multi-center, Randomized, Placebo-controlled, Double-blind Clinical Trial of Escitalopram on the Progression Delaying Effect in Alzheimer's Disease

Lead sponsor

Seoul National University Hospital

Asset

Escitalopram

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Alzheimer's disease

Primary endpoints

•% Change of Hippocampus Volume•% Change of Whole Brain Volume

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00702780

Org study IDSNUDC001

Timeline

Milestones

Study first posted2008-06-20estimated

Study start2008-11 (month precision)

Primary completion2011-09actual (month precision)

Study completion2011-09actual (month precision)

Last update posted2014-06-13estimated

Results first posted2014-06-13estimated

Assets

Drug assets

Escitalopram

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age40 Years

Maximum age90 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Age:40~90 years

•Education:not illiterate

•Clinical Dementia Rating (CDR):0.5~2

•Modified Hachinski Ischemic Score (Rosen et al., 1979):less than 4

•Dementia according to DSM-IV criteria

•Probable Alzheimer's disease according to NINCDS-ADRDA criteria

•Current ongoing donepezil medication at stable doses (5 ~ 10 mg/day) for at least 2 months

Exclusion criteria

•Evidence of delirium, confusion or altered consciousness

•Evidence of Parkinson's disease, stroke, brain tumor and normal pressure hydrocephalus

•Evidence of infectious or inflammatory brain disease

•Evidence of serious cerebrovascular diseases

•Current major depressive disorder or other major psychiatric illnesses

•Evidence of serious or unstable medical illnesses which can significantly change cognitive state

•History of alcohol or other substance dependence

•Any antidepressant medications within the previous 4 weeks

•Absence of a reliable and cooperative collateral informant

•Any conditions which prohibit MRI scan, such as presence of pacemaker or cerebrovascular clip, and claustrophobia

•Evidence of focal brain lesions on MRI including lacunes and white matter hyperintensity lesions of grade 2 or more by Fazeka scale

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Neuroimaging

Other (unclassified)

Neuroimaging

2 endpoints

Primary/protocol endpoint

% Change of Whole Brain Volume

Time frame:52 weeks

percent change from baseline, improvement

Primary/registry result

% Change of Whole Brain Volume

Time frame:52 weeks

percent change from baseline, improvement

Posted result

Group	Value (mean), percentage of change	Standard deviation
Escitalopramn=28 Participants	-3.27	2.69
Placebon=29 Participants	-2.30	3.08

Other (unclassified)

2 endpoints

Primary/protocol endpoint/low confidence

% Change of Hippocampus Volume

Time frame:52 weeks

percent change from baseline, improvement

Primary/registry result/low confidence

% Change of Hippocampus Volume

Time frame:52 weeks

percent change from baseline, improvement

Posted result

Group	Value (mean), percentage of change	Standard deviation
Escitalopramn=28 Participants	-7.63	7.32
Placebon=29 Participants	-7.28	5.76

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.